| Business Name: |
Teva Pharmaceuticals USA Inc |
| Contact Person: |
J Kevin Buchi, Chief Executive Officer |
| Address: |
41 Moores Road, Malvern, Pennsylvania 19355 |
| Phone Number: |
(610) 344-0200 |
| Website Address: |
cephalon.com |
| Annual Revenue (USD): |
$500.000.000 to $999.999.999 |
| Founding Year: |
2011 |
| Location Type: |
Branch |
| Employee Number: |
1 to 4 |
| Business Type: |
B2B & B2C |
| Business Category: |
|
| SIC Code: |
2834 |
| NAICS Code: |
3254120 |
| Share This Business: |
|
| Related Businesses: |
Janssen Biotech Inc - Malvern, PA 19355
Crixmor LLC - Malvern, PA 19355
Recro Pharma Inc - Malvern, PA 19355
Janssen Biotech Inc - Malvern, PA 19355
DermAvance Pharmaceuticals - Malvern, PA 19355
Viropharma Incorporated - Malvern, PA 19355
Janssen Biotech Inc - Malvern, PA 19355
Janssen Biotech - Malvern, PA 19355
Lazarus Therapeutics Inc - Malvern, PA 19355
Vicept Therapeutics Inc - Malvern, PA 19355
Cephalon International Holdings Inc - Malvern, PA 19355
Promedior Inc - Malvern, PA 19355
Fred Oakes - Malvern, PA 19355
Endo Pharmaceuticals Inc - Malvern, PA 19355
Endo Pharmaceuticals Solutions Inc - Malvern, PA 19355
Micron Technologies - Malvern, PA 19355
Qilu Pharma Inc - Malvern, PA 19355
Zeomedix Inc - Malvern, PA 19355
|
The company Teva Pharmaceuticals USA Inc provides BOTH services in the form of from its branch in Pennsylvania.
1 to 4 employees work for Teva Pharmaceuticals USA Inc, and the business now earns $500.000.000 to $999.999.999 per annum.
Teva Pharmaceuticals USA Inc was launched in 2011 and is classified under SIC code and category 2834 , and NAICS number and grouping 3254120 .
To contact Teva Pharmaceuticals USA Inc, please call J Kevin Buchi, Chief Executive Officer with the phone number (610) 344-0200 or visit its branch at 41 Moores Road in Malvern, Pennsylvania 19355.
The location of the branch can also be found using the coordinates 40.052316,-75.564923.
Read more details about this business on the webpage cephalon.com or follow the company’s social media accounts, on Twitter and on Facebook.